Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Profit After Tax (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Profit After Tax data on record, last reported at -$122.8 million in Q4 2025.

  • For Q4 2025, Profit After Tax fell 52.39% year-over-year to -$122.8 million; the TTM value through Dec 2025 reached -$465.3 million, down 55.93%, while the annual FY2025 figure was -$465.3 million, 55.93% down from the prior year.
  • Profit After Tax reached -$122.8 million in Q4 2025 per CRNX's latest filing, up from -$130.1 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$22.9 million in Q1 2021 and bottomed at -$130.1 million in Q3 2025.
  • Average Profit After Tax over 5 years is -$62.5 million, with a median of -$54.2 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: dropped 20.3% in 2023, then tumbled 69.33% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$30.8 million in 2021, then tumbled by 46.1% to -$45.0 million in 2022, then crashed by 33.58% to -$60.1 million in 2023, then plummeted by 34.11% to -$80.6 million in 2024, then tumbled by 52.39% to -$122.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$122.8 million in Q4 2025, -$130.1 million in Q3 2025, and -$115.6 million in Q2 2025.